ABSOLUTELY MEANINGLESS. With no reference to any strategy none of these problems in stroke will even be attempted to be solved. Until we get survivors in charge and get some real leadership your children and grandchildren will be screwed if they have a stroke. Talk is cheap.
Check out these 13 problems in stroke with nothing to address them.
The latest nothing burger here:
Time for the next stage of stroke recovery trials
Published:August, 2020DOI:https://doi.org/10.1016/S1474-4422(20)30218-0
Almost 10 years ago, the FLuoxetine for motor recovery After acute ischaeMic strokE
(FLAME) trial
suggested that early prescription of daily 20 mg fluoxetine, a selective serotonin-reuptake inhibitor (SSRI), could substantially enhance upper and lower limb motor recovery, as measured with the Fugl-Meyer Motor Assessment Scale, in patients with moderate to severe ischaemic stroke. The rationale for using fluoxetine was that it would enhance spontaneous poststroke plasticity mechanisms, with beneficial effects on functional recovery.
FLAME put fluoxetine in the spotlight as a recovery drug, but the study was a small trial (N=118) and did not generate robust evidence to change practice.
suggested that early prescription of daily 20 mg fluoxetine, a selective serotonin-reuptake inhibitor (SSRI), could substantially enhance upper and lower limb motor recovery, as measured with the Fugl-Meyer Motor Assessment Scale, in patients with moderate to severe ischaemic stroke. The rationale for using fluoxetine was that it would enhance spontaneous poststroke plasticity mechanisms, with beneficial effects on functional recovery.
FLAME put fluoxetine in the spotlight as a recovery drug, but the study was a small trial (N=118) and did not generate robust evidence to change practice.
To read this article in full you will need to make a payment
No comments:
Post a Comment